全身MRI评估多发性遗传性外生骨疣与内生软骨瘤病中的恶性转化:审计结果与文献综述
回顾性分析62例多发性遗传性外生骨疣(57例)和内生软骨瘤病(5例)患者、平均随访4.6年的253次全身MRI筛查,筛查检出3例无症状软骨肉瘤,未见全身MRI漏诊的软骨肉瘤;结合文献综述,多发性遗传性外生骨疣的软骨肉瘤风险似乎为2-3.7%,内生软骨瘤病高达50%;作者认为MRI可作为筛查方法,但疗效需长期随访研究包括成本分析来确认。
要点
- 全身MRI可检出多发性遗传性外生骨疣和内生软骨瘤病患者的无症状软骨肉瘤,本组筛查检出3例。
- 筛查期间研究组未出现全身MRI未检出的软骨肉瘤。
- 检出的软骨肉瘤组织学以1级为主,除2例外位于躯干、股骨近端和肩带。
核心结论
- MRI可能可作为检测多发性遗传性外生骨疣和内生软骨瘤病患者恶性转化的筛查方法,但其疗效需在包含成本分析的长期随访研究中确认。
研究设计与样本
- 回顾性分析62例患者(多发性遗传性外生骨疣57例、内生软骨瘤病5例),平均随访4.6年(范围1-10年),共253次全身MRI(每例中位4次,范围1-10次),比较全身MRI时间与确诊软骨肉瘤日期,并附文献综述聚焦恶性转化风险。
诊断标准与关键数值
- 基于本研究资料和文献综述,多发性遗传性外生骨疣的软骨肉瘤风险似乎为2-3.7%,内生软骨瘤病患者高达50%。
临床应用与阅片要点
- 作者认为MRI可能可作为多发性遗传性外生骨疣和内生软骨瘤病患者的筛查方法,用于检测恶性转化,但疗效需在包含成本分析的长期随访研究中确认。
局限性
- 原文结论指出MRI作为筛查方法的疗效需在包含成本分析的长期随访研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To analyze the results of annual screening using whole-body magnetic resonance imaging (WBMRI) in patients with multiple hereditary exostoses (MHE) and enchondromatosis (EC), and estimate the risk for transformation to chondrosarcoma (CS) in these disorders.
MATERIALS AND METHODS: A total of 62 patients (57 with MHE and five with EC) screened during a mean follow-up period of 4.6 years (range, 1-10 years) using 253 WBMRIs (median four WBMRIs per patient, range, 1-10) were analyzed retrospectively. The time of WBMRIs was compared with dates for diagnosed CSs. A supplementary literature review was performed focusing on the risk of malignant transformation.
RESULTS: Ten patients had CS before being enrolled in the screening program, nine with MHE and one with EC. Three asymptomatic CSs were detected by screening; one in a patient with EC and two in patients with MHE, one of whom had CS previously. During the screening period, there was no occurrence of CS not detected by WBMRI in the study group. Histopathologically, the CSs were predominantly grade 1 and were, except for in two patients, located at the truncus, proximal femur, and shoulder girdle. Based on the current material and literature review, the risk of CS seems to be in the range of 2-3.7% for MHE and up to 50% for EC patients.
CONCLUSIONS: MRI may be used as a screening method detecting malignant transformation in MHE and EC patients, but the efficacy has to be confirmed in long-term follow-up studies including cost analysis.
引用
- Jurik AG, Jørgensen PH, Mortensen MM, et al. Whole-body MRI in assessing malignant transformation in multiple hereditary exostoses and enchondromatosis: audit results and literature review. Skeletal Radiol. 2019. PMID: 31273432. doi:10.1007/s00256-019-03268-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。